Chicago Equity Partners LLC cut its stake in Supernus Pharmaceuticals Inc (NASDAQ:SUPN) by 3.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 85,935 shares of the specialty pharmaceutical company’s stock after selling 3,370 shares during the quarter. Chicago Equity Partners LLC owned 0.16% of Supernus Pharmaceuticals worth $2,855,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds also recently made changes to their positions in the company. Meeder Asset Management Inc. grew its stake in shares of Supernus Pharmaceuticals by 511.1% in the fourth quarter. Meeder Asset Management Inc. now owns 880 shares of the specialty pharmaceutical company’s stock worth $30,000 after acquiring an additional 736 shares during the period. Quantbot Technologies LP bought a new stake in shares of Supernus Pharmaceuticals in the third quarter worth approximately $113,000. Gryphon Financial Partners LLC grew its stake in shares of Supernus Pharmaceuticals by 302.5% in the third quarter. Gryphon Financial Partners LLC now owns 4,037 shares of the specialty pharmaceutical company’s stock worth $204,000 after acquiring an additional 3,034 shares during the period. Laurion Capital Management LP bought a new stake in shares of Supernus Pharmaceuticals in the third quarter worth approximately $207,000. Finally, Assenagon Asset Management S.A. bought a new stake in shares of Supernus Pharmaceuticals in the fourth quarter worth approximately $223,000. Hedge funds and other institutional investors own 99.18% of the company’s stock.
SUPN opened at $37.89 on Thursday. The company has a current ratio of 2.82, a quick ratio of 2.65 and a debt-to-equity ratio of 0.77. The company has a market capitalization of $2.00 billion, a P/E ratio of 30.07 and a beta of 1.58. Supernus Pharmaceuticals Inc has a 12-month low of $30.05 and a 12-month high of $61.25.
A number of equities analysts recently issued reports on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Supernus Pharmaceuticals in a report on Friday, November 23rd. Piper Jaffray Companies set a $44.00 price objective on shares of Supernus Pharmaceuticals and gave the stock a “hold” rating in a report on Wednesday, January 16th. ValuEngine downgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, November 6th. BidaskClub downgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, November 7th. Finally, Mizuho raised their price objective on shares of Supernus Pharmaceuticals from $61.00 to $63.00 and gave the stock a “buy” rating in a report on Monday, December 17th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and six have issued a buy rating to the company. Supernus Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $57.43.
WARNING: “Supernus Pharmaceuticals Inc (SUPN) Shares Sold by Chicago Equity Partners LLC” was first reported by Macon Daily and is the sole property of of Macon Daily. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://macondaily.com/2019/02/14/supernus-pharmaceuticals-inc-supn-shares-sold-by-chicago-equity-partners-llc.html.
Supernus Pharmaceuticals Company Profile
Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.
Further Reading: The Structure of a Futures Contract
Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals Inc (NASDAQ:SUPN).
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.